Source: https://www.mayerbrown.com/en/people/c/calica-andrew-j
Timestamp: 2019-04-18 18:26:50+00:00

Document:
Andrew J. Calica is a partner in the New York office and a member of Mayer Brown’s Litigation & Dispute Resolution practice. He represents companies in the pharma and life sciences sectors in complex product liability litigation, areas where Mayer Brown was recently recognized as Practice of the Year for Product Liability Litigation and Life Sciences by Law360. He also advises pharmaceutical companies in internal investigations and in commercial litigation, arbitration and mediation. Andrew’s recent engagements include representing brand name pharmaceutical companies in a nationwide product liability litigation and a multi-national pharmaceutical company in an international commercial arbitration.
In the financial services sector, Andrew has represented banks and broker dealers in securities and commodities litigation and in a variety of commercial disputes involving financial products, contracts and accounting including at trial. Andrew is a member of Mayer Brown’s Electronic Discovery & Information Governance practice. He is co-author of three chapters in the Electronic Discovery Deskbook, a treatise on electronic discovery and records management published by the Practicing Law Institute.
Secured trial victory for global bank on claim of breach of the implied covenant of good faith and fair dealing in connection with a revolving credit agreement.
Obtained dismissal of Commodity Exchange Act claims against global bank in LIBOR class action.
Represented global pharmaceutical company in connection with N.Y. False Claims Act claim by New York Attorney General.
Represented brand name pharmaceutical companies as national counsel supervising cases involving 8,000 product liability plaintiffs.
Bell v. Pfizer (8th Cir. 2013); Fullington v. Pfizer (8th Cir. 2013); Strayhorn v. Wyeth (6th Cir. 2013); Eckhardt v. Qualitest (5th Cir. 2014); Huck v. Trimark (Iowa 2014); Smith v. Wyeth (6th Cir. 2011); Mensing v. Wyeth (8th Cir. 2009). Obtained dismissal for brand name pharmaceutical company in failure to warn cases involving ingestion of generic pharmaceuticals.
Assisted a multi-national pharmaceutical company in a licensing dispute before the ICC International Court of Arbitration.
Represented an owner participant in a contested bankruptcy proceeding concerning tax indemnity claims arising out of the purchase of aircraft.
Represented a global pharmaceutical company in connection with an internal investigation arising out of a clinical trial.
Defended a leading broker dealer against $500 million claims that it colluded to inflate the valuation of mortgage backed securities held by a hedge fund customer.
Defended a global bank in a commercial arbitration that involved an accounting dispute with the bank’s former subsidiary.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.